Chaperoning antigen presentation by MHC class II molecules and their role in oncogenesis.
Tumor vaccine development aimed at stimulating the cellular immune response focuses mainly on MHC class I molecules. This is not surprising since most tumors do not express MHC class II or CD1 molecules. Nevertheless, the most successful targets for cancer immunotherapy, leukemia and melanoma, often do express MHC class II molecules, which leaves no obvious reason to ignore MHC class II molecules as a mediator in anticancer immune therapy. We review the current state of knowledge on the process of MHC class II-restricted antigen presentation and subsequently discuss the consequences of MHC class II expression on tumor surveillance and the induction of an efficient MHC class II mediated antitumor response in vivo and after vaccination.
Marsman
Marije
M
Division of Tumor Biology, The Netherlands Cancer Institute, Amsterdam.
Jordens
Ingrid
I
Griekspoor
Alexander
A
Neefjes
Jacques
J
D017951:Antigen Presentation / Q000276:immunology*; D019496:Cancer Vaccines; D002471:Cell Transformation, Neoplastic / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D007157:Immunologic Surveillance; D007167:Immunotherapy / Q000379:methods; D018832:Molecular Chaperones / Q000276:immunology*
D019496:Cancer Vaccines; D000949:Histocompatibility Antigens Class II; D018832:Molecular Chaperones